Replies to post #141883 on Anavex Life Sciences Corp (AVXL)

[Amatuer17]

I still think M is not sure about efficacy of A2-73 - as such he is going into Analysis-paralysis mode and delaying AD trial start as much as possible.

There is no much data you can generate from 32 or 25 patients - he already used some 80 attributes in Ariana - how many combinations one can analyze? There were 32 patients out of which 25 finished.

[bas2020]

I would hope that they not ONLY use patients who have a favorable bio makeup for best results, but use others as well. It would provide much more information.

[ExtremelyBullishZig]

I am sure the FDA application/protocol could not have been done months ago. This is the process. People just have to deal with it or start their own CNS focused biotech company.

[Fireman02360]

If 273 is the wonder drug everyone thinks it is

Not everyone here thinks 2-73 is some "wonder" or "miracle" drug. We have posters here with more tempered expectations. I suspect the truth is somewhere in between the most enthusiastic and most pessimistic. All we need to beat is SOC, which isn't a high-bar to clear. For Retts, there is NOTHING. For Alzheimer's, if we can prove stabilization (not reversal) for 6+ months in 25% of trial participants, 2-73 gets approved and is the new SOC. I believe what Missling/Anavex is doing might even bring us above 50% stabilization of patients because of the pain-staking inclusion/exclusion data by using DNA/Biomarkers to determine who will best respond to 2-73. Now, lets say there is a reversal in a small population of patients...now we are talking a whole different ball-game. But reversal IS NOT necessary to gain FDA approval.


-Fireman